AsianScientist (Sep. 25, 2013) – GE Healthcare Life Sciences, a business unit of GE Healthcare, and biologics manufacturer JHL Biotech today announced that they will build a new factory in China for JHL Biotech.
The factory, which will be fully operational beginning early 2015, will be located at the Biolake Science Park in Wuhan, China.
Founded by a group of biotech veterans and backed by venture capital firms including Kleiner Perkins Caufield & Byers China Fund, Sequoia Capital, Burrill & Co and China Development Industrial Bank, JHL Biotech is an emerging biopharmaceuticals company that develops and manufactures high-quality, affordable biologic medicines.
Worldwide demand for biopharmaceuticals, such as antibodies for the treatment of cancer and a new generation of innovative vaccines, is increasing dramatically. The KUBio™ modular biopharmaceutical factory (KUBio) is a new approach to readily establish biopharmaceutical manufacturing capacity by delivering customers a fully functional, ready-to-run bioprocessing facility in 14-18 months, which is significantly shorter than constructing a traditional facility.
Pre-designed to meet cGMP requirements, KUBio helps manufacturers such as JHL Biotech bring treatments to market more quickly.
“In realizing our vision of making world-class biopharmaceuticals affordable and accessible to all patients, KUBio was the natural choice. Utilizing manufacturing innovations was always a key part of our strategy and GE Healthcare’s KUBio delivers the technologies we want, with the technical support and training we need,” said Racho Jordanov, Co-founder, President and CEO of JHL Biotech.
——
Source: GE Healthcare Life Sciences.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
